1. Home
  2. PCVX vs BLCO Comparison

PCVX vs BLCO Comparison

Compare PCVX & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

N/A

Current Price

$56.05

Market Cap

7.0B

Sector

Health Care

ML Signal

N/A

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

N/A

Current Price

$16.94

Market Cap

6.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCVX
BLCO
Founded
2013
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.1B
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
PCVX
BLCO
Price
$56.05
$16.94
Analyst Decision
Strong Buy
Buy
Analyst Count
11
14
Target Price
★ $109.00
$19.04
AVG Volume (30 Days)
★ 1.2M
288.1K
Earning Date
11-03-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $5,101,000,000.00
Revenue This Year
N/A
$7.71
Revenue Next Year
N/A
$5.86
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 6.47
52 Week Low
$39.87
$13.77
52 Week High
$65.00
$18.92

Technical Indicators

Market Signals
Indicator
PCVX
BLCO
Relative Strength Index (RSI) 44.39 49.12
Support Level $52.18 $16.94
Resistance Level $58.77 $17.21
Average True Range (ATR) 2.19 0.39
MACD -0.27 -0.03
Stochastic Oscillator 30.24 45.28

Price Performance

Historical Comparison
PCVX
BLCO

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: